At a Glance
- Company: Vivatides Therapeutics
- Location: China/US cross-border biotech
- Deal value: $54M oversubscribed Series A
- Focus area: RNA drug delivery beyond liver targets
- Next steps: Advance LNP and polymer platforms to preclinical proof
What happened?
Vivatides Therapeutics closed an oversubscribed $54 million Series A funding round to develop novel delivery systems for RNA therapeutics that can target tissues beyond the liver. The capital will support expansion of the company’s lipid nanoparticle (LNP) and polymer-based platforms for mRNA, siRNA and other RNA modalities.
Why does it matter?
Liver delivery dominates RNA therapeutics — ~90% of approved and clinical-stage RNA drugs target hepatocytes — but extra-hepatic delivery to muscle, CNS, lung and tumour tissues remains a major bottleneck. Vivatides’ chemistry-driven approach to surface ligands, ionisable lipids and endosomal escape mechanisms could unlock broader therapeutic utility, expanding the addressable market for RNA medicines beyond metabolic, liver and viral diseases.
Who’s behind it?
Vivatides operates as a cross-border biotech leveraging China’s chemistry synthesis capacity and US clinical/regulatory expertise. Backed by specialist life sciences investors, the company combines computational design, high-throughput screening and medicinal chemistry to engineer tissue-selective nanoparticles.
How was it achieved?
The Series A funds proprietary LNP and polymer platforms optimised for apolipoprotein-independent uptake pathways, ApoE shielding and active targeting via peptide, antibody or small-molecule ligands. Preclinical data likely demonstrated superior delivery efficiency to muscle, brain and lung versus benchmark LNPs, supporting the platform’s differentiation.
What’s next?
Vivatides will prioritise lead candidates for IND-enabling studies, targeting high-value indications like neuromuscular disease (DMD, ALS), pulmonary fibrosis and oncology. Partnerships with RNA payload developers and big pharma will likely follow preclinical validation.